Roche, Inception launch hearing loss newco

Roche (SIX:ROG; OTCQX:RHHBY), Versant Ventures and drug discovery company Inception Sciences Inc. (San Diego, Calif.) launched Inception 3 Inc. to discover treatments for sensorineural hearing loss. The newco, which has a license to undisclosed IP from Stanford University, plans to develop therapies that target inner ear hair cell protection and regeneration in the cochlea. Versant will provide equity financing and Roche will provide milestone-based research funding. Roche has an exclusive option to acquire Inception 3 upon the filing of the first IND application. Peppi Prasit, who is CEO and CSO of Inception Sciences, is president and CEO of Inception 3. ...